arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Erasca, Inc.

ERAS
$13.19 ▼ -1.73 (-11.63%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

Erasca, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.1B
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -10.4% ↗
FCF / Share $-0.09 ↗
Trailing P/E —
Price / Book 11.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-183.44M
↓ -492.4% —
FCF / Share Free cash flow per share
$-0.09
↑ +2.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
20
Cash Quality →
52

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters